Ascentage Pharma adds lisaftoclax to China reimbursement list
Ascentage Pharma (NASDAQ:AAPG) secured first-time Chinese national reimbursement coverage for lisaftoclax and renewed coverage for olverembatinib, with the updated agreements taking effect January 1, 2027.










